Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sashikanth Banappagari"'
Autor:
Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Myra Happe, Larisa Strom, Nina M Berkowitz, Mercy Guech, Zonghui Hu, Mike Castro, Manjula Basappa, Lu Wang, Kwang Low, LaSonji A Holman, Floreliz Mendoza, Ingelise J Gordon, Sarah H Plummer, Olga Trofymenko, Kathleen S Strauss, Sudhaunshu Joshi, Biraj Shrestha, Matthew Adams, Andrezza Campos Chagas, Jittawadee R Murphy, Judy Stein, Somia Hickman, Andrew McDougal, Bob Lin, Sandeep R Narpala, Sandra Vazquez, Leonid Serebryannyy, Adrian McDermott, Martin R Gaudinski, Edmund V Capparelli, Emily E Coates, Richard L Wu, Julie E Ledgerwood, Lesia K Dropulic, Robert A Seder, Cheryl Young, Colleen Boyce, Jennifer Winkler, Susan Holian, Nancy Greenberg, Shirley George, Alyson Kwon, Brenda Dorsey, Ana Raquel Da Costa, William Witt, Daryl Grays, Arren Gapasin, Paula Bernal, Jeffrey Floyd, Eric Goldstein, Leslie Howe, Myounghee Lee, Jennifer Marron, Kelly Brooks, Lisa Turek, Patricia Farley, Shantel Frels, Delores Booth, Jason Gall, Kevin Carlton, Gabriela Albright, Nadia Amharref, Kandace Atallah, Sashikanth Banappagari, Niutish Bastani, Daniel Blackstock, Bobby Boonyaratanakornkit, Elizabeth Carey, Adam Charlton, Rajoshi Chaudhuri, Alegria M. Caringal, Mingzhong Chen, Peifeng Chen, Wei Cheng, Daniel Gowetski, Krishana Gulla, Erica Hastings, Joe Horwitz, Vera Ivleva, Dan Kordella, Lisa A. Kueltzo, Sara Lagler, Matt Le, James Lee, Paula Lei, Yile Li, Attila Nagy, Aakash Patel, Peyi Runsewe, Will Shadrick, Shamitha Shetty, Hairong Wang, Calvin Webber, Farah Vejzagic, Yoo-Jung Yang
Publikováno v:
The Lancet Infectious Diseases. 23:578-588
Autor:
Seetharama D. Jois, Yong-Yu Liu, Gu Xin, Shanthi Kanthala, Sashikanth Banappagari, Ameya Gokhale, Yunfeng Zhao
Publikováno v:
Chemical Biology & Drug Design. 85:702-714
The current approach to treating HER2-overexpressed breast cancer is the use of monoclonal antibodies or a combination of antibodies with traditional chemotherapeutic agents or kinase inhibitors. Our approach is to target clinically validated HER2 do
Autor:
Alecia McCall, Sashikanth Banappagari, Krystal R. Fontenot, M. Graça H. Vicente, Seetharama D. Satyanarayanajois, Amit D. Gujar
Publikováno v:
European Journal of Medicinal Chemistry. 65:60-69
Among the EGFRs, HER2 is a major heterodimer partner and also has important implications in the formation of particular tumors. Interaction of HER2 protein with other EGFR proteins can be modulated by small molecule ligands and, hence, these protein-
Protein–protein interactions (PPI) play a crucial role in many biological processes and modulation of PPI using small molecules to target hot spots has therapeutic value. As a model system we will use PPI of human epidermal growth factor receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3ad14a2818306e933c9920fb69b1b17
Publikováno v:
Journal of biomolecular structuredynamics. 28(3)
Human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor kinases (other members include EGFR or HER1, HER3, and HER4) that are involved in signaling cascades for cell growth and differentiation. It is
Publikováno v:
Cancer Research. 72:1227-1227
Protein-protein interactions play a crucial role in regulating many biological processes as well as in disease pathology. Understanding the structural basis and modulating protein-protein interactions has a tremendous impact in developing new therape
Publikováno v:
MedChemComm. 2:752
Human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor kinases and is involved in a signaling cascade for cell growth and differentiation. It is well established that HER2-mediated heterodimerization